Regulation & Policy

Industry news, regulatory updates, and policy analysis.

4 articles
News14 min

14 Peptides Are Legal Again: What the RFK Reclassification Actually Means

In February 2026, HHS Secretary RFK Jr. announced that 14 peptides—including BPC-157, Thymosin Alpha-1, and CJC-1295/Ipamorelin—would return to legal compounding status. Here's what changed, what didn't, and what it means for the peptide community going forward.

Regulation & Policy
Guide10 min

Peptides and Anti-Doping: What Athletes Need to Know in 2025

The World Anti-Doping Agency prohibits numerous peptides that are widely available online. For athletes, the consequences of a positive test can be career-ending. Here's the current landscape.

Regulation & Policy
News14 min

Peptide Regulation Outlook 2026: What Researchers Need to Know

An analysis of the evolving regulatory landscape for peptides in 2026. Understanding FDA changes, international regulations, and what the future holds for peptide research and availability.

Regulation & Policy
News12 min

The Compounding Pharmacy Crisis: Why Access to Peptides Changed in 2025

FDA regulatory changes have dramatically altered access to compounded peptides. Many popular peptides can no longer be legally compounded. Here's what happened and what it means for researchers and patients.

Regulation & Policy

Showing 4 articles in Regulation & Policy

Explore more categories

Browse all research categories or explore our peptide database.

All CategoriesPeptide Database